AEBP-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human AEBP-1 (UniProt Q8IUX7), expressed in HEK293 cells. Suited for ECM remodeling assays, inhibitor studies, and antibody validation alongside the matched RP-AEBP1 antibody.
Expression system
HEK293
Cat. #
REC-AEBP1

In stock

SKU
REC-AEBP1
$498.00

Target Overview

AEBP-1 (Adipocyte Enhancer-Binding Protein 1; also known as Aortic Carboxypeptidase-Like Protein) is a secreted 1,158-amino-acid protein encoded by the AEBP1 gene (UniProt Q8IUX7). It carries a carboxypeptidase-like domain and functions as a positive regulator of collagen fibrillogenesis, placing it at the intersection of extracellular matrix (ECM) organization and connective tissue homeostasis. Because the protein is naturally secreted, heterologous expression in HEK293 cells — a human system capable of supporting the glycosylation and signal-peptide processing required for secreted proteins — is well-suited to producing a conformationally representative form of the recombinant. REC-AEBP1 is produced in HEK293 cells and is intended for in-vitro research applications. Researchers employ this recombinant in several experimental contexts: as a positive control or loading standard in Western blot workflows validating anti-AEBP1 detection reagents; as a defined antigen in binding and pull-down assays exploring AEBP1 interactions with collagen substrates or ECM components; and as a tool protein in inhibitor-screening assays aimed at modulating AEBP1 carboxypeptidase-like activity. The full-length (1,158 aa) human sequence supports research requiring the intact structural context of both the carboxypeptidase domain and flanking regions. Researchers requiring a validated detection reagent for endogenous AEBP1 can pair this recombinant with the Triple Point Biologics matched antibody (RP-AEBP1), which has been validated for Western blot applications against human samples. Using the recombinant as an antigen-positive control alongside RP-AEBP1 is a straightforward approach to confirm assay specificity in new sample matrices.

Background

AEBP1 encodes a large secreted protein with a C-terminal carboxypeptidase-like domain structurally related to the metallocarboxypeptidase family, though its precise enzymatic activity in vivo remains an active area of investigation. Its best-characterised function is as a positive regulator of collagen fibrillogenesis: AEBP1 appears to modulate the organisation and remodeling of the extracellular matrix, making it relevant to research on connective tissue architecture and fibrotic processes. Interest in AEBP1 as a research target has grown substantially across multiple disease contexts. In cardiac biology, AEBP1 has been characterised in the context of myocardial fibrosis; Drakos et al. (2026) investigated AEBP1 inhibition as a strategy to probe fibrotic signaling in heart failure models, establishing the protein as a tractable molecular target in cardiac ECM research (PMID: 42245802). Separately, AEBP1 variants have been linked to classical-like Ehlers-Danlos syndrome type 2 (clEDS2), a heritable connective tissue disorder; a 2026 case study by Nakahara et al. described gastrointestinal involvement associated with a novel AEBP1 splice-site variant, reinforcing the gene's role in systemic connective tissue integrity (PMID: 42191857). Beyond structural connective tissue disease, AEBP1 has emerged in transcriptomic and single-cell studies of fibrosis-driven pathologies. Huang et al. (2026) used single-cell profiling and machine learning to identify AEBP1 as a fibrogenesis modulator within cuproptosis-related fibroblast subpopulations in endometriosis tissue (PMID: 42149287), while a bioinformatics study by Xu et al. (2026) implicated AEBP1 among hub genes in endometriosis pathogenesis via ferroptosis-related pathways (PMID: 42060917). In ocular research, Duveau et al. (2026) identified AEBP1 as part of a transcription factor network relevant to proliferative vitreoretinal disease (PMID: 42104523). Across these published studies, recombinant AEBP1 protein serves as an essential reagent for validating antibody detection, establishing activity baselines, and characterising binding partners or inhibitory compounds in cell-free systems. The breadth of tissues in which AEBP1 dysregulation has been studied — cardiac, endometrial, connective, and retinal — reflects the broad utility of a well-characterised recombinant standard in anchoring these diverse experimental workflows. All applications of this reagent are research-use only.

Applications

  • Western blot positive control for anti-AEBP1 antibody validation in human tissue lysates
  • Antibody specificity confirmation paired with matched Triple Point Biologics antibody RP-AEBP1
  • Collagen fibrillogenesis modulation assay using defined recombinant AEBP1 concentrations
  • Inhibitor IC50 determination targeting AEBP1 carboxypeptidase-like domain in biochemical screens
  • ECM protein–protein interaction pull-down assay to identify AEBP1 collagen-binding partners
  • ELISA calibration standard for quantification of AEBP1 in conditioned media or tissue extracts
  • Recombinant antigen for SPR or BLI binding-kinetics measurements with candidate inhibitory antibodies

References

  1. Drakos S et al. Adipocyte Enhancer Binding Protein 1 (AEBP1) Inhibition as a Potential Anti-Fibrotic Therapy in Heart Failure. Res Sq. 2026. doi:10.21203/rs.3.rs-3390276/v2. PMID: 42245802.
  2. Nakahara H et al. Gastrointestinal involvement in Ehlers-Danlos syndrome classical-like type 2 associated with a novel AEBP1 splice-site variant. J Hum Genet. 2026. doi:10.1038/s10038-026-01480-z. PMID: 42191857.
  3. Huang E et al. Single-cell profiling and machine learning identify cuproptosis-related fibroblast subpopulations and fibrogenesis modulator AEBP1 in endometriosis. Apoptosis. 2026. doi:10.1007/s10495-026-02342-x. PMID: 42149287.
  4. Duveau C et al. Key role of transcription factors network in proliferative vitreoretinal diseases development. Cell Biosci. 2026. doi:10.1186/s13578-026-01581-4. PMID: 42104523.
  5. Xu JY. Bioinformatics analysis implicates ferroptosis and key hub genes in the pathogenesis of endometriosis. J Obstet Gynaecol. 2026. doi:10.1080/01443615.2026.2661210. PMID: 42060917.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What is the expected molecular weight of recombinant AEBP-1 on SDS-PAGE and Western blot?

AEBP-1 is a 1,158-amino-acid protein with a predicted unmodified MW of ~130 kDa. Because REC-AEBP1 is expressed in HEK293 cells — a system that supports mammalian glycosylation — the observed band on reducing SDS-PAGE typically migrates at 140–160 kDa due to N-linked glycosylation. On Western blot under denaturing conditions, expect a diffuse band in the 140–160 kDa range; this smearing is characteristic of heavily glycosylated secreted proteins and is not indicative of degradation. Purity is confirmed at >90% by SDS-PAGE prior to release.

Is recombinant AEBP-1 the full-length protein or a processed fragment? Does it include the signal peptide?

REC-AEBP1 is produced as full-length AEBP-1 (residues 1–1158, UniProt Q8IUX7) expressed in HEK293 cells. The endogenous N-terminal signal peptide directs the nascent protein through the secretory pathway, where it is co-translationally cleaved; the recombinant product collected from conditioned medium therefore represents the mature, processed form without the signal peptide. No additional propeptide or tag truncation is introduced, so the carboxypeptidase-like domain is intact and present in the final product, which is relevant for fibrillogenesis and ECM-binding assays.

What substrate or assay can I use to confirm AEBP-1 carboxypeptidase-like activity in vitro?

AEBP-1 carries a carboxypeptidase-like domain but lacks the catalytic zinc-coordinating residues found in classical metallocarboxypeptidases, meaning it does not exhibit conventional carboxypeptidase hydrolytic activity against standard substrates such as hippuryl-Phe or furylacryloyl-Ala-Phe. Functional characterization is better pursued through collagen fibrillogenesis assays: measure fibril assembly kinetics (turbidity at A313 nm) in the presence of type I collagen (0.1–0.5 mg/mL) and titrated REC-AEBP1 (0.1–2 µg/mL) in 50 mM Tris-HCl pH 7.5, 150 mM NaCl at 37°C. AEBP-1 accelerates fibril formation, providing a quantifiable functional readout.

What buffer conditions are recommended for AEBP-1 fibrillogenesis or binding assays?

REC-AEBP1 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For collagen fibrillogenesis assays, dilute the recombinant into assay buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl) to keep glycerol below 1% final concentration, as higher glycerol can independently influence fibril kinetics. For pull-down or SPR binding experiments with ECM components, PBST (pH 7.4, 0.05% Tween-20) is compatible. Avoid detergents above 0.1% and pH below 6.5, which can reduce protein solubility. A starting concentration of 0.5–1 µg/mL is a practical titration point for initial dose-response experiments.

What starting concentration of recombinant AEBP-1 should I use for a cell-based ECM or fibroblast stimulation assay?

For cell-based assays — such as stimulating fibroblasts or mesenchymal cells to probe AEBP-1's role in ECM remodeling — a starting concentration of 100–500 ng/mL in serum-free or low-serum media is a reasonable range, consistent with concentrations used for other secreted ECM regulators. Endotoxin levels for REC-AEBP1 are <0.1 EU/µg by LAL assay, so endotoxin-driven inflammatory artifacts are minimized. Titrate in 3-fold dilutions from 500 ng/mL downward and confirm cellular response (e.g., collagen gel contraction, fibril deposition by immunofluorescence) at 24–72 hours post-treatment.

Can I use REC-AEBP1 as a positive control for Western blot with the matched anti-AEBP-1 antibody RP-AEBP1?

Yes — this is one of the primary intended uses of REC-AEBP1. The matched rabbit polyclonal antibody RP-AEBP1 (/anti-aebp-1-rabbit-polyclonal-antibody) is validated for Western blot against this exact recombinant in-house, so band identity at 140–160 kDa is confirmed. Load 50–200 ng of REC-AEBP1 per lane alongside your cell lysate or conditioned medium samples. This quantity gives a clean, strong signal without overloading, and serves as both a molecular weight reference and an antibody sensitivity benchmark within the same blot. Dilute REC-AEBP1 in 1× Laemmli sample buffer and boil 5 min before loading.

How much recombinant AEBP-1 should I load for a Western blot positive control lane?

Load 50–200 ng of REC-AEBP1 per lane for a Western blot positive control. At 50 ng, the band at 140–160 kDa is detectable with RP-AEBP1 at a 1:1,000 dilution using standard HRP-conjugated secondary antibodies and chemiluminescent detection. If you are calibrating a new lot of RP-AEBP1 or comparing detection sensitivity across antibody dilutions, running a 3-point titration (50, 100, 200 ng) in adjacent lanes is practical. Avoid loading more than 500 ng, as over-signal and blooming can obscure migration behavior of the glycosylated band.

How should I store and handle REC-AEBP1 to preserve activity, and what is its shelf life after thawing?

Store REC-AEBP1 at -20°C in the single-use aliquots provided. Avoid repeated freeze-thaw cycles — each cycle can reduce soluble protein yield and functional activity, particularly relevant for a secreted ECM regulator like AEBP-1 that relies on tertiary structure for collagen interactions. Once thawed, keep on ice and use within 4–8 hours; do not refreeze. The protein is stable for at least 12 months from date of receipt at -20°C when stored undisturbed. Working dilutions in assay buffer (without glycerol) should not be stored; prepare fresh from the frozen stock for each experiment.

Validation imagery coming soon

Western blot validation figures for REC-AEBP1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →